Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Any contraindications present
X = Generally not suitable
These were generally mild to moderate in severity, most prominent during the dose escalation phase, and tended to diminish over time
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE et al
Both are brand-name semaglutide from the same manufacturer, but they are approved and marketed for different uses and dosing, with Wegovy indicated for chronic weight management
Reported or proposed issue Long-term or repeated-cycle effects Evidence source No long-term human trial Known or theoretical
US$ 29.46
US$ 26.94
US$ 21.12
US$ 22.87
US$ 27.28
